NDASPINALINJECTABLE
Approved
May 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
MARCAINE (bupivacaine hydrochloride in dextrose) by Pfizer is impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. First approved in 1984.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MARCAINE (bupivacaine hydrochloride in dextrose) is a local anesthetic administered via spinal injection for regional anesthesia. It works by blocking nerve impulses by increasing the electrical excitation threshold and slowing nerve impulse propagation, producing loss of sensation in a predictable sequence from pain through muscle tone. Patients undergoing spinal procedures or surgeries requiring regional anesthesia receive this injectable formulation.
$0.694MPart D
LOE ApproachingProduct approaching loss of exclusivity with minimal Part D penetration signals mature/declining lifecycle requiring defensive commercial strategies and cost management focus.
Mechanism of Action
impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Pharmacokinetics, Relative Bioavailability and Safety of INL-001 Compared to Marcaine After Open Hernioplasty
Started Jun 2017
52 enrolled
Hernioplasty
Career Relevance
Working on MARCAINE at LOE presents career challenges and opportunities: limited growth trajectory requires expertise in defensive positioning, generic competition management, and cost-efficiency initiatives. Professionals should expect focus on operational excellence, channel management, and preservation of market share in a contracting specialty anesthetic market.
Worked on MARCAINE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.